

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

HPAF-II

RRID:CVCL_0313

Type: Cell Line

Proper Citation

RRID:CVCL_0313

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0313

Proper Citation: RRID:CVCL_0313

Description: Cell line HPAF-II is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:1764370](#), [PMID:2734279](#), [PMID:11787853](#), [PMID:12068308](#), [PMID:12692724](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15367897](#), [PMID:18380791](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20418756](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31037374](#), [PMID:31068700](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at c.452C>T in PubMed=1764370., Caution: Could not find proof that the CD18 subline of HPAF is really HPAF-II but many indirect evidences points in this direction. If someone read this comment and can help us, please do., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HPAF-II

Synonyms: HPAF II, HPAFII, HPAF-2, HPAF2, HPAF/CD18, CD18/HPAF, HPAF-II/CD18, CD-18, CD18, CD 18

Cross References: BTO:BTO_0003266, CLO:CLO_0003816, EFO:EFO_0002198, MCCL:MCC:0000206, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1997, BioGRID_ORCS_Cell_line:236, BioSample:SAMN03471950, BioSample:SAMN10987875, cancercellines:CVCL_0313, CCRID:3101HUMSCSP5011, Cell_Model_Passport:SIDM00669, CGH-DB:165-1, CGH-DB:9274-4, ChEMBL-Cells:ChEMBL3308744, ChEMBL-Targets:ChEMBL1075467, CLS:305088, Cosmic:710858, Cosmic:724869, Cosmic:868241, Cosmic:913304, Cosmic:922247, Cosmic:1108343, Cosmic:1299299, Cosmic:1320467, Cosmic:1571777, Cosmic:2046534, Cosmic:2434099, Cosmic-CLP:724869, DepMap:ACH-000094, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:724869, GEO:GSM206510, GEO:GSM385517, GEO:GSM385528, GEO:GSM621899, GEO:GSM784696, GEO:GSM827289, GEO:GSM887090, GEO:GSM888161, GEO:GSM1024402, GEO:GSM1374546, GEO:GSM1374547, GEO:GSM1669893, IARC_TP53:944, IGRhCellID:HPAFII, IZSLER:BS TCL 170, LiGeA:CCLE_028, LINCS_LDP:LCL-1736, MetaboLights:MTBLS812, PharmacDB:HPAFII_565_2019, PRIDE:PXD003198, Progenetix:CVCL_0313, PubChem_Cell_line:CVCL_0313, TOKU-E:4028, Wikidata:Q54890231

ID: CVCL_0313

Hierarchy: cvcl_b284

Record Creation Time: 20220427T220440+0000

Record Last Update: 20260913T004225+0000

Ratings and Alerts

No rating or validation information has been found for HPAF-II.

No alerts have been found for HPAF-II.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 71 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kaur T, et al. (2026) Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. Molecular cancer research : MCR, 24(1), 34.

Zhang Y, et al. (2026) Integrative multi-omics analysis identifies ATAD1 as a potential regulator of metastasis in pancreatic cancer. *Scientific reports*, 16(1).

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. *iScience*, 29(6), 115978.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.

Lin Q, et al. (2026) Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(11), 2279.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Trekitkarnmongkol W, et al. (2026) RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. *Nature cell biology*, 28(1), 197.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Manoukian P, et al. (2026) Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. *Cancer research*, 86(3), 571.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Huang JX, et al. (2026) Indocyanine Green-Labeled Antibodies Cotargeting CDCP1 and Mesothelin for Fluorescence-Guided Imaging of Pancreatic Cancer. *Molecular pharmaceutics*, 23(2), 1059.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. *Cancer research*, 86(8), 1868.

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. *Cancer research*, 86(8), 2024.

Krishna Kumar N, et al. (2026) SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. *Cell reports*, 45(6), 117387.

Moore GL, et al. (2025) A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies. *Molecular cancer therapeutics*, 24(3), 331.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. *Nature communications*, 16(1), 9996.

Tang J, et al. (2025) CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. *Cancer letters*, 622, 217713.

Bowman CL, et al. (2025) The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. *Cancer research*, 85(24), 4899.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. *iScience*, 28(2), 111842.

Li X, et al. (2025) Plakophilin 3 drives acinar cell transformation and promotes cancer initiation and progression in pancreas. *Cell reports*, 44(11), 116487.